Overview

Synovial sarcoma is an uncommon type of soft-tissue sarcoma that typically develops near large joints of the arms and legs. Despite the name, it usually does not arise from synovial membrane itself; the term reflects an early impression based on microscopic similarities. It can occur at any age but is more often seen in adolescents and young adults. Because it is rare, patients are frequently referred to specialized centers for diagnosis and management.

Characteristics and pathology

Microscopically, synovial sarcoma may show a biphasic pattern with both epithelial-like and spindle-cell components, or a monophasic pattern composed mainly of spindle cells. Immunohistochemistry can assist in identification: many tumors express cytokeratins, epithelial membrane antigen (EMA), and markers such as TLE1. A defining laboratory finding is a specific chromosomal translocation that produces an SS18-SSX (formerly SYT-SSX) fusion gene; detection of this fusion by molecular testing helps confirm the diagnosis.

Clinical presentation

Common signs include a slowly growing, deep soft-tissue mass that may be painless for months. Tumors are frequently located near but not within joints, often in the thigh, knee region, or forearm. Advanced disease can produce pain, decreased joint motion, or symptoms related to lung metastases, which are the most frequent distant spread site.

Diagnosis

Evaluation begins with clinical examination and imaging: magnetic resonance imaging (MRI) is preferred to define local extent, while chest imaging assesses for pulmonary spread. Definitive diagnosis requires a tissue biopsy and combined pathological, immunohistochemical, and molecular analyses. Because management decisions are complex, multidisciplinary review by surgeons, medical oncologists, and pathologists is important. For general patient information see patient resources and for context within soft-tissue cancers see soft-tissue sarcoma overview.

Treatment and prognosis

Primary treatment is wide surgical excision with the goal of removing the tumor with negative margins. Radiation therapy is commonly used to reduce local recurrence risk, especially for larger or anatomically challenging tumors. Systemic chemotherapy, often anthracycline- and ifosfamide-based regimens, may be offered for high-risk or metastatic disease; targeted agents and immunotherapy are areas of active research. Prognosis depends on tumor size, location, resectability, patient age, and presence of metastases at diagnosis. Long-term follow-up is necessary because recurrences can occur years after treatment.

History and notable facts

The term "synovial sarcoma" originated in the early 20th century when pathologists noted microscopic resemblance to synovial tissue. Subsequent research established that the tumor has a distinct origin and characteristic molecular signature. Because of its rarity and variable appearance, synovial sarcoma can be mistaken for other soft-tissue tumors, so molecular testing and specialist pathology review are important. Clinical care benefits from referral to centers experienced in sarcoma management and participation in clinical trials when appropriate.

Key points

  • Rare soft-tissue cancer usually near joints of the limbs.
  • Often affects adolescents and young adults but may appear at any age.
  • Diagnosis uses imaging, biopsy, immunohistochemistry, and molecular tests for SS18-SSX fusion.
  • Treatment combines surgery, radiation, and sometimes chemotherapy; multidisciplinary care is essential.